Aytu BioPharma (NASDAQ:AYTU – Get Free Report) is expected to issue its Q1 2027 results after the market closes on Thursday, November 12th. Analysts expect the company to announce earnings of ($0.2567) per share and revenue of $13.27 million for the quarter. Individuals may visit the company’s upcoming Q1 2027 earnings report for the latest details on the call scheduled for Monday, November 16, 2026 at 4:30 PM ET.
Aytu BioPharma Price Performance
Shares of AYTU opened at $1.81 on Wednesday. Aytu BioPharma has a 1-year low of $1.75 and a 1-year high of $3.06. The firm has a 50-day simple moving average of $2.04 and a two-hundred day simple moving average of $2.29. The company has a current ratio of 1.13, a quick ratio of 1.00 and a debt-to-equity ratio of 0.26.
Analysts Set New Price Targets
A number of research firms recently weighed in on AYTU. Zacks Research cut shares of Aytu BioPharma from a “hold” rating to a “strong sell” rating in a research report on Monday, October 5th. Citigroup reiterated a “positive” rating on shares of Aytu BioPharma in a report on Tuesday, September 22nd. Finally, Weiss Ratings lowered Aytu BioPharma from a “sell (d)” rating to a “sell (d-)” rating in a research report on Tuesday, October 6th. Two analysts have rated the stock with a Buy rating and two have given a Sell rating to the company’s stock. Based on data from MarketBeat, Aytu BioPharma presently has an average rating of “Hold” and an average target price of $14.50.
Read Our Latest Stock Analysis on AYTU
About Aytu BioPharma
Aytu BioPharma, Inc. is a specialty pharmaceutical company focused on commercializing prescription medicines and other healthcare products. The company’s portfolio has primarily centered on treatments for attention-deficit/hyperactivity disorder (ADHD), along with select pediatric and primary-care products. Aytu’s ADHD products have included Adzenys XR-ODT, an extended-release orally disintegrating tablet containing amphetamine; Cotempla XR-ODT, an extended-release orally disintegrating tablet containing methylphenidate; and Evekeo, an amphetamine sulfate product.
Read More
- Five stocks we like better than Aytu BioPharma
- Why Kinder Morgan’s Chairman Just Bought $15 Million in Stock
- Rocket Lab’s Record Backlog Could Fuel a Rebound, But Neutron Raises the Stakes
- Don’t Let Their Low Yields Fool You: 3 Dividend Stocks Worth Watching
- A $4 Billion Jolt: NRG Energy Powers Data Center Ambitions
Receive News & Ratings for Aytu BioPharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aytu BioPharma and related companies with MarketBeat.com's FREE daily email newsletter.
